India proposes sops to manufacturers and Aayog scheme to boost bulk drug industry

6 March 2020

As India looks to avert a potential drug shortage crisis in the wake of escalating COVID-19 cases in the country, a standing committee set up by the Department of Pharmaceuticals and government think-tank Niti Aayog has proposed a $409 million scheme to boost the bulk drug industry.

The proposal mandates the government to provide incentives to pharma companies which are ready to invest in active pharmaceutical ingredients (APIs) and fermentation units, reports The Pharma Letter’s India correspondent.

While the drug regulatory authority will grant logistics support, the government has said it will look to invest 25% of the project cost, in a bid to boost domestic manufacture of raw materials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK